Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02246101 · ClinicalTrials.gov registry record

World Trade Center (WTC) RENAL

A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
406
Enrollment target

NCT02246101 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 406 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02246101 has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
406 participants
Enrollment target

Study Summary

Environmental toxins exert damaging health effects in workers. Thousands of responders who worked or volunteered on the World Trade Center (WTC) rescue and recovery effort following the September 11, 2001 attacks suffer from health conditions or may be at increased risk for worsening health. In a pilot study, investigators identified the first evidence of kidney damage in subjects with very high exposure at Ground Zero. Specifically, noted was a preliminary association between the intensity of particulate matter exposure and albuminuria, a marker of early chronic kidney disease (CKD), systemic endothelial dysfunction, and increased cardiovascular risk. The long-term goal is to minimize the risk of CKD and cardiovascular disease (CVD) among individuals exposed to inhaled toxins. The primary objective of this research is to quantify the risk of kidney damage among first responders to the WTC attack and to determine the relationship to particulate matter exposure as well as determine an association between renal and cardiovascular damage in first responders and to explore potential mechanisms. The central hypothesis is that exposure to inhaled particulate matter causes systemic inflammation and endothelial dysfunction that result in chronic kidney and cardiovascular damage. This hypothesis will be investigated in a subgroup of participants from a previously conducted NIOSH-funded study "Pulmonary Function Abnormalities, Diastolic Dysfunction and WTC Exposure: Implications for Diagnosis and Treatment" ("WTC-CHEST," PI Mary Ann McLaughlin). The proposed study will capitalize on unique resources in WTC-CHEST, including the standardized collection of data on particulate matter exposure and shared risk factors for CKD and cardiovascular disease, and cardiopulmonary function testing. The output from this proposal is anticipated to have a broad impact on understanding the health effects of inhaled particulate matter.

Trial Details

FieldValue
Enrollment Target 406 participants
Start Date 2014-07
Est. Completion 2016-09-16

What the Registry Record Tells You About NCT02246101

The ClinicalTrials.gov registry entry for NCT02246101 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02246101 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02246101 about?

NCT02246101 is a clinical study titled "World Trade Center (WTC) RENAL". Environmental toxins exert damaging health effects in workers. Thousands of responders who worked or volunteered on the World Trade Center (WTC) rescue and recovery effort following the September 11, 2001 attacks suffer from health conditions or may be at increased risk for worsening health. In a pi...

What is the current status of trial NCT02246101?

This trial is currently completed. The enrollment target is 406 participants. The study started on 2014-07. Estimated completion is 2016-09-16.

Who is sponsoring clinical trial NCT02246101?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.